Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel J Bundred

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Expert Opinion on Therapeutic Targets|September 17, 2013
Targeting IL-8 signalling to inhibit breast cancer stem cell activityJagdeep K Singh, Bruno M Simões, Robert B Clarke, et al.
Advances in Experimental Medicine and Biology|May 24, 2008
Response and resistance to the endocrine prevention of breast cancerAnthony Howell, Nigel J Bundred, Jack Cuzick, et al.
Stem Cells (Dayton, Ohio)|September 5, 2014
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapyKathryn E Williams, Nigel J Bundred, Göran Landberg, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2013
Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)Gillian Farnie, Rachael L Johnson, Kathryn E Williams, et al.
Cancer|December 12, 2003
Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinomaRamachandran Prasad, Gary P Boland, Angela Cramer, et al.
Anticancer Research|August 15, 2002
Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifenNigel J Bundred, Elizabeth Anderson, Robert I Nicholson, et al.
Breast Cancer Research : BCR|April 14, 2006
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivoFredrik Wärnberg, Daniel White, Elizabeth Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breastNicola L P Barnes, Sahar Khavari, Gary P Boland, et al.
Journal of the National Cancer Institute|April 19, 2007
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathwaysGillian Farnie, Robert B Clarke, Katherine Spence, et al.
Oncotarget|December 30, 2016
Tissue Factor promotes breast cancer stem cell activity in vitroHudhaifah Shaker, Hannah Harrison, Robert Clarke, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Expert Opinion on Therapeutic Targets|September 17, 2013
Targeting IL-8 signalling to inhibit breast cancer stem cell activityJagdeep K Singh, Bruno M Simões, Robert B Clarke, et al.
Advances in Experimental Medicine and Biology|May 24, 2008
Response and resistance to the endocrine prevention of breast cancerAnthony Howell, Nigel J Bundred, Jack Cuzick, et al.
Stem Cells (Dayton, Ohio)|September 5, 2014
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapyKathryn E Williams, Nigel J Bundred, Göran Landberg, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2013
Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)Gillian Farnie, Rachael L Johnson, Kathryn E Williams, et al.
Cancer|December 12, 2003
Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinomaRamachandran Prasad, Gary P Boland, Angela Cramer, et al.
Anticancer Research|August 15, 2002
Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifenNigel J Bundred, Elizabeth Anderson, Robert I Nicholson, et al.
Breast Cancer Research : BCR|April 14, 2006
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivoFredrik Wärnberg, Daniel White, Elizabeth Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breastNicola L P Barnes, Sahar Khavari, Gary P Boland, et al.
Journal of the National Cancer Institute|April 19, 2007
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathwaysGillian Farnie, Robert B Clarke, Katherine Spence, et al.
Oncotarget|December 30, 2016
Tissue Factor promotes breast cancer stem cell activity in vitroHudhaifah Shaker, Hannah Harrison, Robert Clarke, et al.
Pageof 5